logo
Sign in

HDT BIO CORP

Seattle, WA · Biotech · Private

RNA molecule agonist targeting RIG-I (retinoic acid inducible gene-I) formulated in nanoparticles for hepatitis B virus treatment

Claim this profile

Follows are private to you and power your alerts

Updated · hdt.bio

Sector
Biotech
Headquarters
Seattle, WA
Total capital
$17.8M
Federal grants
$3.3M
13 awards · 2018–2023
Rank in peer group#228 of 326
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$14.5M
7 awards · Health and Human S, Defense
Rank in Biotech#52 of 4373
Granted patents
18
22 pending · first 2022
Rank in peer group#10 of 326

Capital timeline

20182019202020212022202320242025FEDERAL ↑EQUITY ↓Cumulative $17.3M$600K$11M$399K$1.5M$300K$749K
2018202020222024FEDERAL ↑EQUITY ↓Cumulative $17.3M$600K$11M$1.5M$749K

Latest events

  • Federal contractDefense · Research Service$129K
  • Federal contractHealth and Human S · Hdt Bio Corp - Aoi #21 Vaccine On Demand: R&d Use Of Lion-reprna In Rapid Response Vaccine Development$749K
  • Federal grantHealth and Human S · Phase I · PA21259, SBIR Phase I, Developing a RIG-I agonist to prevent COVID-19$300K
  • Federal grantHealth and Human S · Phase I · Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets$193K
  • Federal grantHealth and Human S · Phase I · Development of a RIG-I agonist RNA as a cure for chronic Hepatitis B$275K
  • Federal grantHealth and Human S · Phase I · Development of a RIG-I agonist RNA as a cure for chronic Hepatitis B$275K
  • Federal contractHealth and Human S · Adaptable Rna-based Antibody Platform For Protection Against Contemporary/emerging Human Enteroviruses$1.5M
Show 11 earlier federal awards
  • Federal grantHealth and Human S · Phase I · Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets$105K
  • Federal grantHealth and Human S · Phase I · Development of an adaptable RNA vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis$300K
  • Federal grantHealth and Human S · Phase I · Development of an adaptable RNA vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis$300K
  • Federal grantHealth and Human S · Phase I · Targeting and Imaging Ovarian Cancer with Junction Opener Conjugated-Lipid Iron Oxide Nanoparticles (JOC-LIONs)$399K
  • Federal grantHealth and Human S · Phase I · Development of CoroDetecT, a skin test for SARS-CoV-2 infection$224K
  • Federal grantHealth and Human S · Phase I · Development of CoroDetecT, a skin test for SARS-CoV-2 infection$224K
  • Federal contractHealth and Human S · COVID-19. To Develop And Progress HDT-301, A Replicon Rna Encoding SARS-COV-2 Spike Protein Bound To Lipid Inorganic Nanoparticle (lion) Formulation To Protect Against COVID-19, Through A Phase I Clinical Trial.$11M
  • Federal contractHealth and Human S · SBIR Phase I Topic 85$300K
  • Federal contractHealth and Human S · Rational Development Of A Combination Nanoparticle Adjuvant For Influenza.$600K
  • Federal grantHealth and Human S · Phase I · Engineering Nanoparticle Alum Adjuvants for Pandemic Influenza Vaccines$225K
  • Federal contractHealth and Human S · Diagnostics To Enable Malaria And Neglected Tropical Diseases$222K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

2 records have no date or no amount, so they aren’t placed on the timeline.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Granted patents#10 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 18 granted of 40
  • PendingCancer Therapy Compositions And Uses ThereofUSPTOApplication 19380218
  • PendingNanoparticle Complexes For Enhanced SafetyUSPTOApplication 19259545
  • PendingCompositions And Methods For Delivery Of RnaUSPTOApplication 19324932
Show all 40 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .